HBM Holdings (HKG:2142) investigational new drug application for HBM7575, a long-acting bispecific antibody for asthma treatment, has been approved by China's National Medical Products Administration.
HBM7575/SKB575, co-developed with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990), targets thymic stromal lymphopoietin and an undisclosed target to treat asthma, according to a Wednesday Hong Kong bourse filing.
Shares of the company rose over 1% in recent trade.